/APGE
APGE Stock - Apogee Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$78.54+1.54%
+$1.19 (+1.54%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).84
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.63
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+16.8%upside
Target: $91.73
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for APGE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$77.75 – $79.33
TARGET (TP)$91.75
STOP LOSS$72.26
RISK/REWARD1:2.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.42
52W High$80.99
52W Low$26.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-216,870,000 | $-93,003,000 | $-30,727,000 |
| Net Income | $-182,146,000 | $-83,985,000 | $-39,785,000 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-3.30 | $-1.66 | $-0.79 |
Company Overview
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
14
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
14 Bullish0 Neutral/Bearish
Price Targets
$73
Average Target
↓ 6.7% Downside
Now
$29
Low
$73
Average
$115
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 17th 2025 | Stephens | Initiation | Overweight | $95 |
| December 10th 2025 | Deutsche Bank | Initiation | Buy | $103 |
| November 3rd 2025 | Craig Hallum | Initiation | Buy | $109 |
| October 21st 2025 | Mizuho | Initiation | Outperform | $105 |
| September 25th 2025 | RBC Capital Mkts | Initiation | Outperform | $60 |
| July 7th 2025 | BTIG Research | Reiterated | Buy | $115← $100 |
| March 13th 2025 | Citigroup | Initiation | Buy | $95 |
| November 25th 2024 | Canaccord Genuity | Initiation | Buy | $89 |
| May 10th 2024 | BofA Securities | Initiation | Buy | $80 |
| December 20th 2023 | BTIG Research | Initiation | Buy | $43 |
| August 8th 2023 | TD Cowen | Initiation | Outperform | - |
| August 8th 2023 | Wedbush | Initiation | Outperform | $40 |
| August 8th 2023 | Guggenheim | Initiation | Buy | $29 |
| August 8th 2023 | Stifel | Initiation | Buy | $34 |
| August 8th 2023 | Jefferies | Initiation | Buy | $29 |
Earnings History & Surprises
APGEBeat Rate
50%
Last 10 quarters
Avg Surprise
-14.1%
EPS vs Estimate
Beats / Misses
5/5
Last 12 quarters
Latest EPS
$-1.11
Q4 2025
EPS Surprise History
Q1 24
+28.9%
$-0.32vs$-0.45
Q2 24
-6.7%
$-0.64vs$-0.60
Q3 24
+6.3%
$-0.60vs$-0.64
Q4 24
+2.2%
$-0.86vs$-0.88
Q1 25
-26.6%
$-1.19vs$-0.94
Q2 25
+20.2%
$-0.95vs$-1.19
Q3 25
-9.7%
$-1.13vs$-1.03
Q4 25
+0.9%
$-1.11vs$-1.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-1.05 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-1.12 | $-1.11 | +0.9% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-1.03 | $-1.13 | -9.7% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-1.19 | $-0.95 | +20.2% | ✓ BEAT |
Q1 2025 | Mar 3, 2025 | $-0.94 | $-1.19 | -26.6% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.88 | $-0.86 | +2.2% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.64 | $-0.60 | +6.3% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.60 | $-0.64 | -6.7% | ✗ MISS |
Q1 2024 | Mar 5, 2024 | $-0.45 | $-0.32 | +28.9% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.38 | $-0.51 | -34.2% | ✗ MISS |
Q3 2023 | Jul 17, 2023 | $-1.70 | $-3.78 | -122.4% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | — | $-0.25 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.28 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.39 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.04 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.08 | — | — |
Latest News
Stephens & Co. Initiates Coverage On Apogee Therapeutics with Overweight Rating, Announces Price Target of $95
📈 PositiveBenzinga•Dec 17, 2025, 01:32 PM
Deutsche Bank Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $103
📈 PositiveBenzinga•Dec 10, 2025, 11:53 AM•Also:
Update: Apogee Therapeutics Q3 EPS $(1.11) Beats $(1.20) Estimate
📈 PositiveBenzinga•Nov 10, 2025, 12:33 PM
Apogee Therapeutics Q3 2025 Net Loss Was $65M Vs. $49M YoY, $913M Cash, Cash Equivalents And Marketable Securities Supports Runway Into 2H 2028
➖ NeutralBenzinga•Nov 10, 2025, 12:18 PM
Apogee Therapeutics Highlights APG333 Phase 1 Results Supporting Combination Development With APG777 For Respiratory Diseases
📈 PositiveBenzinga•Nov 10, 2025, 12:13 PM
Craig-Hallum Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $109
📈 PositiveBenzinga•Nov 3, 2025, 05:45 PM
RBC Capital Maintains Outperform on Apogee Therapeutics, Raises Price Target to $70
📈 PositiveBenzinga•Nov 3, 2025, 02:37 PM
Mizuho Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $105
📈 PositiveBenzinga•Oct 21, 2025, 12:42 PM
Apogee Therapeutics shares are trading higher. BTIG reiterated its Buy rating on the stock and maintained its $115 price target.
📈 PositiveBenzinga•Oct 9, 2025, 05:34 PM
BTIG Reiterates Buy on Apogee Therapeutics, Maintains $115 Price Target
📈 PositiveBenzinga•Oct 9, 2025, 02:53 PM
Reported Earlier, Apogee Therapeutics Prices 6,951,221 Common Shares At $41 Each And 365,853 Pre-Funded Warrants At $$40.99 Each In $300M Public Offering
➖ NeutralBenzinga•Oct 9, 2025, 06:14 AM
APGE stock has given up its prior loss. Apogee Therapeutics shares were trading lower after the company announced a proposed underwritten public offering.
➖ NeutralBenzinga•Oct 8, 2025, 08:37 PM
Apogee Therapeutics shares are trading lower after the company announced a proposed underwritten public offering.
📉 NegativeBenzinga•Oct 8, 2025, 08:07 PM
Apogee Therapeutics Launches An Underwritten Public Offering Of Its Common Stock; No Amount Disclosed
➖ NeutralBenzinga•Oct 8, 2025, 08:03 PM
RBC Capital Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $60
📈 PositiveBenzinga•Sep 25, 2025, 01:40 PM
Apogee Therapeutics Says Data From Phase 2 APEX Trial Of APG777 For Moderate-To-Severe Atopic Dermatitis Accepted For Late-Breaker Oral Presentation At Upcoming EADV Congress 2025
📈 PositiveBenzinga•Sep 11, 2025, 11:31 AM
B of A Securities Maintains Buy on Apogee Therapeutics, Raises Price Target to $87
📈 PositiveBenzinga•Aug 28, 2025, 03:54 PM
Apogee falls after results from atopic dermatitis trial
📉 NegativeSeeking Alpha•Jul 7, 2025, 03:19 PM
Frequently Asked Questions about APGE
What is APGE's current stock price?
Apogee Therapeutics, Inc. (APGE) is currently trading at $78.54 per share. The stock has moved +1.54% today.
What is the analyst price target for APGE?
The average analyst price target for APGE is $91.75, based on 1 analyst.
What sector is Apogee Therapeutics, Inc. in?
Apogee Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is APGE's market cap?
Apogee Therapeutics, Inc. has a market capitalization of $4.31 billion, making it a mid-cap company.
Does APGE pay dividends?
No, Apogee Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
CELC
Celcuity Inc.
$101.16
Mkt Cap: $4.7B
CGON
CG Oncology, Inc. Common stock
$39.03
Mkt Cap: $2.9B
CNTA
Centessa Pharmaceuticals plc
$24.85
Mkt Cap: $3.3B
IRON
Disc Medicine, Inc.
$80.04
Mkt Cap: $3.0B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to APGE for comparison